The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression
Dateien zu dieser Ressource
Datum
2021Autor
Sauer, Heinrich
Kampmann, Henning
Khosravi, Farhad
Sharifpanah, Fatemeh
Wartenberg, Maria
Zitierlink
http://dx.doi.org/10.22029/jlupub-6824Erstpublikation in
Clinical and experimental pharmacology and physiology 48 (2021), 422-434